Wall Street Zen Upgrades Tharimmune (NASDAQ:THAR) to Hold

Tharimmune (NASDAQ:THAR) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report released on Friday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tharimmune in a research report on Saturday, September 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Tharimmune Stock Performance

Shares of NASDAQ:THAR opened at $2.91 on Friday. Tharimmune has a fifty-two week low of $0.95 and a fifty-two week high of $9.08. The business has a 50-day simple moving average of $2.98 and a two-hundred day simple moving average of $1.98. The firm has a market cap of $17.17 million, a price-to-earnings ratio of -0.48 and a beta of 1.41.

Tharimmune (NASDAQ:THAR) last issued its earnings results on Thursday, August 14th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.06).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Franklin Resources Inc. purchased a new position in Tharimmune, Inc. (NASDAQ:THAR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 45,000 shares of the company’s stock, valued at approximately $88,000. Franklin Resources Inc. owned 1.07% of Tharimmune at the end of the most recent reporting period. Institutional investors own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).